Benzinga | Aug 4, 2020 11:37AM EDT

Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $145

Barclays analyst Balaji Prasad maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight and raises the price target from $134 to $145.